ViiV Healthcare

Apretude (cabotegravir) is a long-acting injectable integrase inhibitor from ViiV Healthcare used for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents at risk. Given as an intramuscular injection every two months after the initial doses, it keeps protective drug levels in the body between shots.

Cabotegravir blocks an enzyme called HIV integrase, which the virus needs to insert its genetic material into the DNA of human cells. Without this ste

Tivicay (dolutegravir) is an integrase inhibitor from ViiV Healthcare for HIV-1 infection, always used with other antiretrovirals. It blocks the viral integrase enzyme so HIV cannot splice its genes into infected cells, keeping viral levels suppressed.

For HIV to multiply, it must insert its genetic code into the DNA of the cells it infects. An enzyme called integrase performs that insertion. Doluteg

Dovato combines dolutegravir and lamivudine into a single daily tablet from ViiV Healthcare for HIV-1 infection in adults. Dolutegravir blocks the viral integrase enzyme that splices HIV genes into host DNA, while lamivudine stops reverse transcriptase from copying the viral genome; together they suppress HIV with a two-drug regimen.

Dolutegravir and lamivudine are two medicines that work together to treat HIV. Dolutegravir blocks an enzyme called integrase, which HIV needs to inse